-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Protagonist Therapeutics (NASDAQ:PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies.
Source: JHVEPhoto / Shutterstock.com
According to a news release, Protagonist Therapeutics has to go ahead to resume dosing in its rusfertide clinical trials. This was previously on hold following concerns from the FDA brought up on Sept. 17.
The FDA required extra information and steps about the trials before they could resume. Protagonist Therapeutics met those requirements by submitting individual patient clinical safety reports, updating the investigator brochure and patient informed consent forms, performing a comprehensive review of the most recent safety database, as well as including new safety and stopping rules in the study protocols.
The 7 Best Consumer Discretionary Stocks To Buy for Q4 2021
Dinesh Patel, Ph.D., president and CEO of Protagonist Therapeutics, said the following about today's news.
"Patient safety continues to be our topmost priority. We believe that the cumulative evidence regarding the safety and clinical risk-benefit of rusfertide is supportive of expedited clinical development."
Protagonist Therapeutics notes that it's moving forward with study plans, which include its Phase 3 registrational study for polycythemia vera. It expects to start that in the first quarter of 2022.
PTGX stock is performing well today following the FDA update. As a result, some 17 million shares of the stock are trading hands. That's a hefty increase over its daily average trading volume of about 1 million shares.
PTGX stock was up 87.5% as of Monday morning. That has it well on its way to recovering the losses it experienced dosing was halted in September.
Investors looking for more recent stock market news will want to stick around!
We've got plenty of stock coverage that traders need to know about. That includes this morning's biggest pre-market stock movers, an update on a Bitcoin (CCC:BTC-USD) ETF, as well as reactions to Camber Energy (NYSE:CEI) strong rise last week. You can find all of that information by checking out the links below!
More Recent Stock Market News
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Bitcoin ETF Approved? Um, Sorta. 7 Things to Know About the Volt Equity ETF (BTCR).
What CEI Stock Investors Are Saying After Camber Energy's Red-Hot Week
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股市新聞、股票諮詢和交易提示
Protagonist Therapeutics (NASDAQ:PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies.
主角治療學納斯達克市場代碼:PTGX)的股票週一大幅上漲,這要歸功於美國食品和藥物管理局(FDA)關於蘆薈肽臨牀研究的最新消息。
Source: JHVEPhoto / Shutterstock.com
來源:JHVEPhoto/Shutterstock.com
According to a news release, Protagonist Therapeutics has to go ahead to resume dosing in its rusfertide clinical trials. This was previously on hold following concerns from the FDA brought up on Sept. 17.
根據一份新聞稿,主角治療公司必須繼續在其黃麴黴毒素臨牀試驗中恢復劑量。此前,在FDA於9月1日提出擔憂後,這一點被擱置。17.
The FDA required extra information and steps about the trials before they could resume. Protagonist Therapeutics met those requirements by submitting individual patient clinical safety reports, updating the investigator brochure and patient informed consent forms, performing a comprehensive review of the most recent safety database, as well as including new safety and stopping rules in the study protocols.
FDA要求提供有關試驗的額外信息和步驟,然後才能恢復試驗。Protagant Treeutics公司通過提交個別患者的臨牀安全報告,更新研究人員手冊和患者知情同意書,對最新的安全數據庫進行全面審查,以及在研究方案中納入新的安全和停止規則,滿足了這些要求。
The 7 Best Consumer Discretionary Stocks To Buy for Q4 2021
2021年第四季度最值得購買的7只非必需消費品股票
Dinesh Patel, Ph.D., president and CEO of Protagonist Therapeutics, said the following about today's news.
主人公治療公司總裁兼首席執行官迪內什·帕特爾博士就今天的新聞説了下面的話。
"Patient safety continues to be our topmost priority. We believe that the cumulative evidence regarding the safety and clinical risk-benefit of rusfertide is supportive of expedited clinical development."
患者安全仍然是我們最優先考慮的問題。我們相信,有關蘆薈肽安全性和臨牀風險效益的累積證據支持加快臨牀開發。“
Protagonist Therapeutics notes that it's moving forward with study plans, which include its Phase 3 registrational study for polycythemia vera. It expects to start that in the first quarter of 2022.
Protagant Treateutics指出,該公司正在推進研究計劃,其中包括真性紅細胞增多症的第三階段註冊研究。該公司預計將在2022年第一季度啟動這一計劃。
PTGX stock is performing well today following the FDA update. As a result, some 17 million shares of the stock are trading hands. That's a hefty increase over its daily average trading volume of about 1 million shares.
隨着FDA的更新,PTGX的股票今天表現良好。因此,該股約有1700萬股易手。這比其約100萬股的日均成交量大幅增加。
PTGX stock was up 87.5% as of Monday morning. That has it well on its way to recovering the losses it experienced dosing was halted in September.
截至週一上午,PTGX股價上漲87.5%。這讓它很好地恢復了在9月份被停止服藥的損失。
Investors looking for more recent stock market news will want to stick around!
尋找更多最新股市消息的投資者將會想要留下來!
We've got plenty of stock coverage that traders need to know about. That includes this morning's biggest pre-market stock movers, an update on a Bitcoin (CCC:BTC-USD) ETF, as well as reactions to Camber Energy (NYSE:CEI) strong rise last week. You can find all of that information by checking out the links below!
我們有大量的股票報道,交易員需要了解。這包括今天上午最大的盤前股票漲幅,最新的比特幣(CCC:BTC-USD)ETF,以及對弧形能源(紐約證券交易所代碼:CEI)上週強勁上漲。您可以通過查看下面的鏈接找到所有這些信息!
More Recent Stock Market News
最近的股市新聞
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Bitcoin ETF Approved? Um, Sorta. 7 Things to Know About the Volt Equity ETF (BTCR).
What CEI Stock Investors Are Saying After Camber Energy's Red-Hot Week
今日最大的盤前炒股:週一漲幅最大的10只股票和輸家最多的10只股票
比特幣ETF獲批?嗯,索爾塔。關於Volt Equity ETF(BTCR)需要知道的7件事。
中東歐股票投資者在Camber Energy火熱的一週後説些什麼
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,威廉·懷特沒有(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點,以InvestorPlace.com為準出版指南.
The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace.
PTGX股票的帖子:FDA新聞,主角治療投資者今天歡呼,它首先出現在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧